Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease

医学 疾病 代谢综合征 脂肪肝 内科学 肥胖 重症监护医学 心脏病学
作者
Anders Mellemkjær,Mikkel Breinholt Kjær,David Haldrup,Henning Grønbæk,Karen Louise Thomsen
出处
期刊:European Journal of Internal Medicine [Elsevier BV]
卷期号:122: 28-34 被引量:72
标识
DOI:10.1016/j.ejim.2023.11.012
摘要

The novel term Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is proposed to replace non-alcoholic fatty liver disease (NAFLD) to highlight the close association with the metabolic syndrome. MASLD encompasses patients with liver steatosis and at least one of five cardiometabolic risk factors which implies that these patients are at increased risk of cardiovascular disease (CVD). Indeed, the prevalence of CVD in MASLD patients is increased and CVD is recognized as the most common cause of death in MASLD patients. We here present an update on the pathophysiology of CVD in MASLD, discuss the risk factors, and suggest screening for CVD in patients with MASLD. Currently, there is no FDA-approved pharmacological treatment for MASLD, and no specific treatment recommended for CVD in patients with MASLD. Thus, the treatment strategy is based on weight loss and a reduction and treatment of CVD risk factors. We recommend screening of MASLD patients for CVD using the SCORE2 system with guidance to specific treatment algorithms. In all patients with CVD risk factors, lifestyle intervention to induce weight loss through diet and exercise is recommended. Especially a Mediterranean diet may improve hyperlipidemia and if further treatment is needed, statins should be used as first-line treatment. Further, anti-hypertensive drugs should be used to treat hypertension. With the epidemic of obesity and type 2 diabetes mellitus (T2DM) the risk of MASLD and CVD is expected to increase, and preventive measures, screening, and effective treatments are highly needed to reduce morbidity and mortality in MASLD patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
田様的应助被科技工作者采纳,获得10
刚刚
麻辣鱼头完成签到,获得积分10
刚刚
嘎嘎鸭完成签到 ,获得积分10
刚刚
搜集达人的应助被枳枳采纳,获得10
刚刚
FashionBoy的应助被科研通管家采纳,获得10
刚刚
我是老大的应助被科研通管家采纳,获得10
刚刚
刚刚
1秒前
bkagyin的应助被科研通管家采纳,获得10
1秒前
pluto的应助被科研通管家采纳,获得10
1秒前
molihuakai的应助被打包带走采纳,获得10
1秒前
null的应助被科研通管家采纳,获得10
1秒前
传奇3的应助被科研通管家采纳,获得10
1秒前
852的应助被Gaoge采纳,获得10
1秒前
null的应助被科研通管家采纳,获得10
1秒前
思源的应助被科研通管家采纳,获得10
1秒前
Akim的应助被科研通管家采纳,获得30
2秒前
2秒前
CodeCraft的应助被酷酷柚子采纳,获得10
2秒前
yy完成签到,获得积分10
2秒前
李爱国的应助被科研通管家采纳,获得10
2秒前
wyz发布了新的文献求助20
2秒前
夏冰雹完成签到 ,获得积分10
2秒前
2秒前
2秒前
小包子完成签到,获得积分10
2秒前
zjw发布了新的文献求助10
2秒前
田様的应助被火星上香菇采纳,获得20
2秒前
ym发布了新的文献求助10
2秒前
2秒前
3秒前
三山四水发布了新的文献求助10
3秒前
bkagyin的应助被斑斑的小奶音采纳,获得10
3秒前
出口的胖猪完成签到,获得积分10
3秒前
帅气yumin完成签到,获得积分10
3秒前
3秒前
4秒前
tong完成签到,获得积分20
4秒前
lili完成签到,获得积分10
4秒前
5秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8161749
求助须知:如何正确求助?哪些是违规求助? 9556240
关于积分的说明 21733360
捐赠科研通 7751657
什么是DOI,文献DOI怎么找? 3427566
关于科研通互助平台的介绍 2552632
邀请新用户注册赠送积分活动 2472047